{"brief_title": "STA-5326 in Crohn's Disease Patients", "brief_summary": "The purpose of this study is to determine the safety and tolerability of STA-5326 given once daily or twice daily to Crohn's Disease patients with moderate disease.", "condition": ["Crohn's Disease"], "intervention_type": ["Drug"], "intervention_name": ["STA-5326"], "criteria": "Inclusion Criteria: - Patients 18-65 years old - Crohn's Disease for 6 months - CDAI scores between 220-450 - +/- 5-ASA, stable dose for > 2 weeks - +/- Corticosteroids, less than or equal to 40 mg per day with a stable dose for 2 weeks - +/- Infliximab with no treatment within 4 weeks - +/- 6-Mercaptopurine, with a stable dose for 8 weeks - +/- Antibiotics, with a stable dose for 2 weeks Exclusion Criteria: - Patients who have had methotrexate, cyclosporine, or other experimental drug within 3 months of screening - Pregnancy, breast feeding - History of total proctocolectomy with stoma. Previous ileocolectomy would not be a contraindication to the study - Bowel obstruction - Surgical bowel resection within 90 days - Total parenteral nutrition (TPN), CYA, tacrolimus", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "keyword": "Crohn's Disease", "mesh_term": ["Crohn Disease"], "id": "NCT00088062"}